For NSCLC, more than 10 immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have been approved for clinical therapy [17–19]. Here, CD274 is linked to non-small cell lung carcinoma.